People with lupus may be offered twice-yearly infusion
The National Institute for Health and Care Excellence has approved a combination treatment that restores normal kidney function in almost half of patients with lupus nephritis. The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus nephritis. Obinutuzumab (Gazyvaro), a twice-yearly infusion that, combined with daily immunosuppressant tablets, significantly outperforms the usual treatments for the disease.